A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
Sign Up to like & getrecommendations! Published in 2017 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2017.1335637
Abstract: Abstract Objective: To examine the efficacy and safety of the once-weekly (q.w.) dipeptidyl peptidase-4 inhibitor, omarigliptin, in patients with type 2 diabetes (T2DM) and inadequate glycemic control on metformin monotherapy. Methods: In a randomized, double-blind… read more here.
Keywords: efficacy safety; safety weekly; omarigliptin; weekly dipeptidyl ... See more keywords